Randomized trial · people

Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c

Checked against the paper Randomized trialPublished by PepVault

The takeaway

For people with type 2 diabetes still above target on lower dulaglutide doses, this trial found that switching to tirzepatide lowered HbA1c and weight more than raising the dulaglutide dose.

Kind
Randomized trial
Studied in
People
Number studied
282
Published
2025
Journal
Ann Intern Med

What they tested

For adults with type 2 diabetes not well controlled on lower doses of dulaglutide, the team tested whether switching to tirzepatide or raising the dulaglutide dose worked better.

How the study was done

A randomized, open-label phase 4 trial in 282 adults with type 2 diabetes at 38 sites in 5 countries, with the main results measured at week 40. All had an HbA1c (hemoglobin A1c) of 7.0% to 9.5% while on a steady dulaglutide dose of 0.75 or 1.5 mg for at least 6 months. They were assigned either to move up to dulaglutide 4.5 mg or the highest dose they could tolerate, or to switch to tirzepatide.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 40, HbA1c dropped by 1.44% in the tirzepatide arm (15 mg or the highest tolerated dose) and by 0.67% in the dulaglutide arm (4.5 mg or the highest tolerated dose), an estimated difference of -0.77%. Weight changed by -10.5 kg with tirzepatide and -3.6 kg with dulaglutide, an estimated difference of -6.9 kg. Serious side effects happened in 10 (7.2%) people on tirzepatide and 10 (7.0%) on dulaglutide. Nausea and diarrhea were the most common side effects.

What it doesn’t show

The trial was open-label, meaning participants and staff knew which treatment each person got. It was funded by Eli Lilly and Company.

The paper

Billings et al. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Ann Intern Med. 2025.

The compounds

More studies on Dulaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo